FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045911091> ?p ?o ?g. }

• W2045911091 endingPage "309" @default.
• W2045911091 startingPage "299" @default.
• W2045911091 abstract "1 The haeme-containing soluble guanylyl cyclase (alpha1beta1-heterodimer) is a major intracellular receptor and effector for nitric oxide (NO) and carbon monoxide (CO) and mediates many of their biological actions by increasing cyclic GMP. We have synthesized new oxadiazolo-benz-oxazins and have assessed their inhibitory actions on guanylyl cyclase activity in vitro, on the formation of cyclic GMP in cultured cells and on the NO-dependent relaxation of vascular and non-vascular smooth muscle. 2 Soluble guanylyl cyclase, purified to homogeneity from bovine lung, was inhibited by 4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one (NS 2028) in a concentration-dependent and irreversible manner (IC50 30 nM for basal and 200 nM for NO-stimulated enzyme activity). Evaluation of the inhibition kinetics according to Kitz & Wilson yielded a value of 8 nM for Ki, the equilibrium constant describing the initial reversible reaction between inhibitor and enzyme, and 0.2 min(-1) for the rate constant k3 of the subsequent irreversible inhibition. Inhibition was accompanied by a shift in the soret absorption maximum of the enzyme's haem cofactor from 430 to 390 nm. 3 S-nitroso-glutathione-enhanced soluble guanylyl cyclase activity in homogenates of mouse cerebellum was inhibited by NS 2028 (IC50 17 nM) and by 17 structural analogues in a similar manner, albeit with different potency, depending on the type of substitution at positions 1, 7 and 8 of the benzoxazin structure. Small electronegative ligands such as Br and Cl at position 7 or 8 increased and substitution of the oxygen at position 1 by -S-,- NH- or -CH2- decreased the inhibition. 4 In tissue slices prepared from mouse cerebellum, neuronal NO synthase-dependent activation of soluble guanylyl cyclase by the glutamate receptor agonist N-methyl-D-aspartate was inhibited by NS 2028 (IC50 20 nM) and by two of its analogues. Similarly, 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells was inhibited by NS 2028 (IC50 30 nM). 5 In prostaglandin F2alpha-constricted, endothelium-intact porcine coronary arteries NS 2028 elicited a concentration-dependent increase (65%) in contractile tone (EC50 170 nM), which was abolished by removal of the endothelium. NS 2028 (1 microM) suppressed the relaxant response to nitroglycerin from 88.3+/-2.1 to 26.8+/-6.4% and induced a 9 fold rightward shift (EC50 15 microM) of the concentration-relaxation response curve to nitroglycerin. It abolished the relaxation to sodium nitroprusside (1 microM), but did not affect the vasorelaxation to the KATP channel opener cromakalim. Approximately 50% of the relaxant response to sodium nitroprusside was recovered after 2 h washout of NS 2028. 6 In phenylephrine-preconstricted, endothelium-denuded aorta of the rabbit NS 2028 (1 microM) did not affect relaxant responses to atrial natriuretic factor, an activator of particulate guanylyl cyclase, or forskolin, an activator of adenylyl cyclase. 7 NO-dependent relaxant responses in non-vascular smooth muscle were also inhibited by NS 2028. The nitroglycerin-induced relaxation of guinea-pig trachea preconstricted by histamine was fully inhibited by NS 2028 (1 microM), whereas the relaxations to terbutaline, theophylline and vasoactive intestinal polypeptide (VIP) were not affected. The relaxant responses to electrical field stimulation of non-adrenergic, non-cholinergic nerves in the same tissue were attenuated by 50% in the presence of NS 2028 (1 microM). 8 NS 2028 and its analogues, one of which is the previously characterized 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ), appear to be potent and specific inhibitors of soluble guanylyl cyclase present in various cell types. Oxidation and/or a change in the coordination of the haeme-iron of guanylyl cyclase is a likely inhibitory mechanism." @default.
• W2045911091 created "2016-06-24" @default.
• W2045911091 creator A5018207284 @default.
• W2045911091 creator A5021676352 @default.
• W2045911091 creator A5024417822 @default.
• W2045911091 creator A5049523368 @default.
• W2045911091 creator A5050471583 @default.
• W2045911091 creator A5076957580 @default.
• W2045911091 creator A5087580516 @default.
• W2045911091 creator A5026692377 @default.
• W2045911091 date "1998-01-01" @default.
• W2045911091 modified "2023-09-26" @default.
• W2045911091 title "Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase" @default.
• W2045911091 cites W1502165328 @default.
• W2045911091 cites W1550877969 @default.
• W2045911091 cites W1584737584 @default.
• W2045911091 cites W1599529839 @default.
• W2045911091 cites W193714546 @default.
• W2045911091 cites W1970467033 @default.
• W2045911091 cites W1974861666 @default.
• W2045911091 cites W1992494631 @default.
• W2045911091 cites W2006995865 @default.
• W2045911091 cites W2017055301 @default.
• W2045911091 cites W2017236986 @default.
• W2045911091 cites W2029354892 @default.
• W2045911091 cites W2029420844 @default.
• W2045911091 cites W2031383268 @default.
• W2045911091 cites W2042254448 @default.
• W2045911091 cites W2051605684 @default.
• W2045911091 cites W2054098746 @default.
• W2045911091 cites W2061530843 @default.
• W2045911091 cites W2062294082 @default.
• W2045911091 cites W2065566941 @default.
• W2045911091 cites W2086885752 @default.
• W2045911091 cites W2087654215 @default.
• W2045911091 cites W2093518775 @default.
• W2045911091 cites W2100157594 @default.
• W2045911091 cites W2107732949 @default.
• W2045911091 cites W4241101943 @default.
• W2045911091 cites W4245847222 @default.
• W2045911091 doi "https://doi.org/10.1038/sj.bjp.0701603" @default.
• W2045911091 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1565161" @default.
• W2045911091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9489619" @default.
• W2045911091 hasPublicationYear "1998" @default.
• W2045911091 type Work @default.
• W2045911091 sameAs 2045911091 @default.
• W2045911091 citedByCount "107" @default.
• W2045911091 countsByYear W20459110912012 @default.
• W2045911091 countsByYear W20459110912013 @default.
• W2045911091 countsByYear W20459110912015 @default.
• W2045911091 countsByYear W20459110912016 @default.
• W2045911091 countsByYear W20459110912017 @default.
• W2045911091 countsByYear W20459110912018 @default.
• W2045911091 countsByYear W20459110912019 @default.
• W2045911091 countsByYear W20459110912020 @default.
• W2045911091 countsByYear W20459110912021 @default.
• W2045911091 countsByYear W20459110912022 @default.
• W2045911091 crossrefType "journal-article" @default.
• W2045911091 hasAuthorship W2045911091A5018207284 @default.
• W2045911091 hasAuthorship W2045911091A5021676352 @default.
• W2045911091 hasAuthorship W2045911091A5024417822 @default.
• W2045911091 hasAuthorship W2045911091A5026692377 @default.
• W2045911091 hasAuthorship W2045911091A5049523368 @default.
• W2045911091 hasAuthorship W2045911091A5050471583 @default.
• W2045911091 hasAuthorship W2045911091A5076957580 @default.
• W2045911091 hasAuthorship W2045911091A5087580516 @default.
• W2045911091 hasBestOaLocation W20459110911 @default.
• W2045911091 hasConcept C13121076 @default.
• W2045911091 hasConcept C155647269 @default.
• W2045911091 hasConcept C173803235 @default.
• W2045911091 hasConcept C178790620 @default.
• W2045911091 hasConcept C181199279 @default.
• W2045911091 hasConcept C185592680 @default.
• W2045911091 hasConcept C2775932965 @default.
• W2045911091 hasConcept C2778827303 @default.
• W2045911091 hasConcept C2780069284 @default.
• W2045911091 hasConcept C41183919 @default.
• W2045911091 hasConcept C519581460 @default.
• W2045911091 hasConcept C55493867 @default.
• W2045911091 hasConcept C56856141 @default.
• W2045911091 hasConcept C71240020 @default.
• W2045911091 hasConceptScore W2045911091C13121076 @default.
• W2045911091 hasConceptScore W2045911091C155647269 @default.
• W2045911091 hasConceptScore W2045911091C173803235 @default.
• W2045911091 hasConceptScore W2045911091C178790620 @default.
• W2045911091 hasConceptScore W2045911091C181199279 @default.
• W2045911091 hasConceptScore W2045911091C185592680 @default.
• W2045911091 hasConceptScore W2045911091C2775932965 @default.
• W2045911091 hasConceptScore W2045911091C2778827303 @default.
• W2045911091 hasConceptScore W2045911091C2780069284 @default.
• W2045911091 hasConceptScore W2045911091C41183919 @default.
• W2045911091 hasConceptScore W2045911091C519581460 @default.
• W2045911091 hasConceptScore W2045911091C55493867 @default.
• W2045911091 hasConceptScore W2045911091C56856141 @default.
• W2045911091 hasConceptScore W2045911091C71240020 @default.
• W2045911091 hasIssue "2" @default.
• W2045911091 hasLocation W20459110911 @default.
• W2045911091 hasLocation W20459110912 @default.

• next